妥洛特罗治疗慢性气道阻塞性疾病的疗效和安全性系统评价  

Systematical Evaluation of Efficacy and Safety of Tulobuterol in the Treatment of Chronic Airway Obstructive Diseases

作　　者：晏远智[1] 马开利 唐恒[1] 胡曦丹 吴晖[1] YAN Yuanzhi;MA Kaili;TANG Heng;HU Xidan;WU Hui(Department of Pharmacy,the First Affiliated Hospital of Kunming Medical University,Kunming 650031,China;Institute of Medical Biology,Chinese Academy of Medical Sciences,Kunming 650000,China)

机构地区：[1]昆明医科大学第一附属医院药剂科,昆明650031 [2]中国医学科学院医学生物学研究所药物安全性评价研究中心,昆明650000

出　　处：《医药导报》2020年第6期854-859,共6页Herald of Medicine

基　　金：云南省教育厅科研基金项目(2020J0157)。

摘　　要：目的系统评价妥洛特罗治疗慢性气道阻塞性疾病的疗效和安全性。方法通过Meta分析方法,计算机检索Cochrane图书馆、EMbase、Pubmed、CNKI、CBM、万方数据资源系统等,筛选关于妥洛特罗治疗慢性气道阻塞性疾病的随机对照试验,采用Rev Man5.0版软件进行Meta分析。结果共19项随机对照试验纳入分析。Meta分析结果显示:妥洛特罗组与对照组比较,两者有效率差异有统计学意义[OR=2.50,95%CI(1.61,3.90),P<0.000 1];在改善肺功能方面,两者在呼气峰流量(PEF)上有微弱差异[MD=10.23,95%CI(0.65,19.82),P=0.04],而对第一秒呼气容积(FEV1)差异无统计学意义;妥洛特罗组患者在治疗前后,短效β2受体激动药使用频次明显减少[MD=-0.53,95%CI(-0.65,-0.42),P<0.000 01];在患者用药依从性方面,妥洛特罗组患者依从性较对照LABA组好[OR=3.75,95%CI(1.34,10.47),P=0.01];两组不良反应发生率差异无统计学意义。结论妥洛特罗对慢性气道阻塞性疾病疗效确切,安全性好。Objective To systematically evaluate the efficacy and safety of tulobuterol in the treatment of chronic airway obstructive disease.Methods The Cochrane library database,EMbase,Pubmed,CNKI,CBM,WANFANG DATA,and other databases were searched for randomized controlled trials of tulobuterol in the treatment of chronic airway obstructive diseases.Meta-analysis was performed using Rev Man version 5.0 software.Results A total of 19 randomized controlled trials were included in the analysis.The results of the meta-analysis showed that there was a statistically significant difference in the effective rate between the two groups[OR=2.50,95%CI(1.61,3.90),P<0.0001];In terms of improving lung function,there was a slight difference in peak expiratory flow(PEF)between the two groups[MD=10.23,95%CI(0.65,19.82),P=0.04],but there was no statistical difference in the first second expiratory volume(FEV 1);The frequency of using short-actingβ2 receptor agonists was significantly reduced before and after treatment in TP group,and the difference was significant between the two groups[MD=-0.67,95%CI(-0.88,-0.46),P<0.00001];In terms of medication compliance,the compliance of patients in TP group was better than that of the LABA group,and the difference was statistically significant[OR=3.75,95%CI(1.34,10.47),P=0.01];the difference of the incidence of adverse reactions between the two groups was not statistically significant.Conclusion Tulobuterol is effective and safe for chronic airway obstructive diseases.

关 键 词：妥洛特罗 慢性气道阻塞性疾病 支气管哮喘 慢性阻塞性肺疾病 系统评价 

分 类 号：R974.3[医药卫生—药品] R562[医药卫生—药学]